Jaguar Health said an initial analysis of anti-diarrhoeal drug Mytesi (crofelemer) in cancer patients showed the Phase III trial did not meet its primary endpoint.

Shares in the Nasdaq-listed company opened 66% lower compared to a pre-announcement market close. Jaguar has a market cap of $12m.

Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector.

Here are the key catalysts of the unfolding week.